Ceramide-dependent regulation of human epidermal keratinocyte CD1d expression during terminal differentiation.
Human keratinocytes (KC), when cultured under conditions to remain undifferentiated or to terminally differentiate, changed their cellular distribution of CD1d. As studied by confocal microscopy, undifferentiated KC had a pool of cytoplasmic CD1d, whereas after terminal differentiation, this molecule localized in the cell membrane, which recapitulates CD1d expression in vivo. A comparison of undifferentiated and differentiated cultured KC did not reveal any differences in the association with beta(2)-microglobulin, invariant chain of class II MHC, or patterns of glycosylation, suggesting that these biochemical properties are not regulating the cellular distribution of CD1d. Time-course studies of CD1d gene expression indicated that KC slowly increased gene expression with CaCl(2)-induced terminal differentiation. Increased CD1d gene expression was dependent on ceramide synthesis, because fumonisin B1, a ceramide synthetase inhibitor, blocked the increase in CD1d gene expression during terminal differentiation. Similarly, exogenous ceramide or the ceramidase inhibitor, B13, induced CD1d gene expression by undifferentiated, but not terminally differentiated, KC. A protein kinase C-zeta (PKC-zeta) inhibitor (a pseudosubstrate oligopeptide), but not a PKC-alphabeta inhibitor, significantly decreased CD1d gene expression by undifferentiated or ceramide-stimulated cultured, undifferentiated KC. As expected, downstream signaling events of PKC-zeta (JNK phosphorylation and NF-kappaBeta accumulation in the nucleus) were also attenuated. The calcineurin phosphatase inhibitor cyclosporine A, which blocks KC terminal differentiation, also blocked CD1d gene expression by cultured KC. In conclusion, this novel function of cellular ceramides extends the importance of this class of biologically active lipids beyond that of terminal differentiation and barrier function in normal human skin.
Fishelevich
Rita
R
Department of Dermatology, University of Maryland School of Medicine, Baltimore, 21201, USA.
Malanina
Alla
A
Luzina
Irina
I
Atamas
Sergei
S
Smyth
Miriam J
MJ
Porcelli
Steven A
SA
Gaspari
Anthony A
AA
D018949:Antigens, CD1 / Q000235:genetics* / Q000378:metabolism*; D019703:Calcineurin / Q000378:metabolism; D065095:Calcineurin Inhibitors; D002122:Calcium Chloride / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects*; D002478:Cells, Cultured; D002518:Ceramides / Q000494:pharmacology*; D016572:Cyclosporine / Q000494:pharmacology; D000078404:Epidermal Cells; D005786:Gene Expression Regulation / Q000187:drug effects*; D006031:Glycosylation; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D013997:Time Factors; D015854:Up-Regulation; D001613:beta 2-Microglobulin / Q000378:metabolism
D018949:Antigens, CD1; D065095:Calcineurin Inhibitors; D002518:Ceramides; D000949:Histocompatibility Antigens Class II; D001613:beta 2-Microglobulin; D016572:Cyclosporine; D019703:Calcineurin; D002122:Calcium Chloride